Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances

Journal of Geriatric Psychiatry and Neurology

Volumn 20, Issue 2, 2007, Pages 107-114

  Lipkovich, Ilya ^a   Ahl, Jonna ^a   Nichols, Russell ^a   Hardy, Thomas ^a   Poole Hoffmann, Vicki ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotics; Dementia; Geriatric; Older adults; Weight gain

Indexed keywords

HALOPERIDOL; OLANZAPINE; PLACEBO; RISPERIDONE;

AGED; ARTICLE; BEHAVIOR DISORDER; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT CHANGE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MENTAL DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 34249940161     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988706298629     Document Type: Article

References (43)

1. Alexopolous GS, Streim J., Carpenter D., et al. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004 ; 65 (suppl 2). 5-99.
2. Bullock R. Treatment of behavioral and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin. 2005 ; 21: 1-10.
3. FDA Public Health Advisory, April 11, 2005. Available at: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed April 19, 2005.
4. Gill SS, Rochon PA, Herrmann N., et al. Atypical antipsychotics drugs and risk of ischaemic stroke: population base retrospective cohort study. BMJ. 2005 ; 330: 445.
5. Hartikainen S., Rahkonen T., Kautiainen H., Sulkava R. The use of psychotropics and survival in demented elderly individuals. Int Clin Psychopharmacol. 2005 ; 20: 227-231.
6. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005 ; 293: 596-608.
7. Brodaty H., Ames D., Snowdon J., et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003 ; 64: 134-143.
8. Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry. 2001 ; 16 (suppl 1). S62 - S70.
9. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000 ; 57: 968-976.
10. Tariot PN, Salzman C., Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000 ; 22: 1068-1084.
11. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999 ; 60: 107-115.
12. Allison DB, Casey DE Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001 ; 62 (suppl 7). 22-31.
13. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001 ; 62: 231-238.
14. Lipkovich I., Citrome L., Perlis R., Deberdt W., Houston JP, Ahl J., Hardy T. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006 ; 26: 316-320.
15. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005 ; 13: 722-730.
16. De Deyn PP, Carrasco MM, Deberdt W., et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004 ; 19: 115-126.
17. Gurevitz SL, Costakis T., Leiter J. Do atypical antipsychotics cause weight gain in nursing home dementia residents ? Consult Pharm. 2004 ; 19: 809-812.
18. Lasser RA, Mao L., Gharabawi G. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. Schizophr Res. 2004 ; 66: 163-167.
19. Madhusoodanan S., Brenner R., Gupta S., et al. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr. 2004 ; 9: 862-867.
20. Hwang JP, Yang CH, Lee TW, Tsai SJ The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol. 2003 ; 23: 113-118.
21. Jeste DV, Barak Y., Madhusoodanan S., et al. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003 ; 11: 638-647.
22. Barak Y., Shamir E., Zemishlani H., et al. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002 ; 26: 1199-1202.
23. Breier A., Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002 ; 52: 438-445.
24. Madhusoodanan S., Brenner R., Suresh P., et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry. 2000 ; 12: 11-18.
25. Street JS, Tollefson GD, Tohen M., et al. Olanzapine for psychotic conditions in the elderly. Psychiatric Ann. 2000 ; 30: 191-196.
26. Barak Y., Shamir E., Mirecki I., et al. Switching elderly chronic psychotic patients to olanzapine. Int J Neuropsychopharmacol. 2004 ; 7: 165-169.
27. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis if Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 ; 34: 939-944.
28. Guy W, ed. National Institute of Mental Health. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication Adm 76-338. Washington, DC: US Department of Health, Education, and Welfare ; 1976: 217-222.
29. Folstein MF, Folstein SE, McHugh PR Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12: 189-198.
30. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001 ; 62: 92-100.
31. Mallinckrodt CH, Sanger TM, Dube S., et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003 ; 53: 754-760.
32. Kinon BJ, Stauffer VL, McGuire HC, et al. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc. 2003 ; 4: 189-194.
33. Kinon BJ, Jeste DV, Kollack-Walker S., et al. Olanzapine treatment for tardive dyskinesia schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004 ; 28: 985-996.
34. Kennedy J., Deberdt W., Siegal A., et al. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Intl J Geriatr Psychiatry. 2005 ; 20: 1020-1027.
35. Hennen J., Perlis RH, Sachs G., et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004 ; 65: 1679-1687.
36. Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry. 1999 ; 60 (suppl 21). 5-9.
37. Bellanger TM, Bray GA Obesity related morbidity and mortality. J La State Med Soc. 2005 ; 157 (Spec No 1). S42 - S429.
38. Micca JL, Hoffmann VP, Lipkovich I., Ahl J., Baker RW, Hardy TA Retrospective analysis of diabetes risk in elderly dementia patients in olanzapine clinical trials. Am J Geriatr Psychiatry. 2006 ; 14: 62-70.
39. Keck PE, McElroy SL Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry. 2003 ; 64: 1426-1435.
40. White H., Pieper C., Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998 ; 46: 1223-1227.
41. White H., McConnell ES, Bales CW, Kuchibhatla M. A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized Alzheimer's disease subjects. J Am Med Dir Assoc. 2004 ; 5: 89-97.
42. van Staveren WA, de Graaf C., de Groot Lcpgm. Regulation of appetite in frail persons. Clin Geriatr Med. 2002 ; 18: 675-684.
43. Keller HH, Gibbs AJ, Boudreau LD, et al. Prevention of weight loss in dementia with comprehensive nutritional treatment. J Am Geriatr Soc. 2003 ; 51: 945-952.